Uniqure (NASDAQ:QURE) had its price objective boosted by analysts at Wells Fargo & Co from $65.00 to $90.00 in a research report issued to clients and investors on Friday, The Fly reports. The firm currently has a “positive” rating on the biotechnology company’s stock. Wells Fargo & Co‘s price target would indicate a potential upside of 41.62% from the stock’s previous close.
A number of other research analysts also recently commented on QURE. Leerink Swann increased their target price on Uniqure from $61.00 to $76.00 and gave the company a “positive” rating in a research report on Thursday, November 15th. HC Wainwright set a $48.00 target price on Uniqure and gave the company a “buy” rating in a research report on Thursday, November 15th. Cantor Fitzgerald restated a “buy” rating and set a $65.00 price target on shares of Uniqure in a report on Thursday, November 15th. B. Riley increased their price target on Uniqure from $50.00 to $72.00 and gave the company a “buy” rating in a report on Friday, November 16th. Finally, Chardan Capital restated a “buy” rating and set a $70.00 price target on shares of Uniqure in a report on Monday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $68.70.
NASDAQ QURE opened at $63.55 on Friday. The company has a quick ratio of 11.85, a current ratio of 11.85 and a debt-to-equity ratio of 0.20. The company has a market cap of $2.44 billion, a PE ratio of -27.16 and a beta of 1.07. Uniqure has a one year low of $20.29 and a one year high of $67.93.
Uniqure (NASDAQ:QURE) last posted its earnings results on Thursday, February 28th. The biotechnology company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.08. Uniqure had a negative return on equity of 47.73% and a negative net margin of 738.25%. On average, sell-side analysts expect that Uniqure will post -2.8 EPS for the current year.
In related news, insider Christian Klemt sold 5,739 shares of the firm’s stock in a transaction dated Thursday, January 3rd. The stock was sold at an average price of $27.91, for a total transaction of $160,175.49. Following the sale, the insider now owns 40,000 shares of the company’s stock, valued at $1,116,400. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Alexander Edward Kuta III sold 1,052 shares of the firm’s stock in a transaction dated Monday, January 28th. The shares were sold at an average price of $31.29, for a total value of $32,917.08. Following the sale, the senior vice president now directly owns 26,578 shares in the company, valued at approximately $831,625.62. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,014 shares of company stock worth $1,454,779. 1.56% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of QURE. Northern Trust Corp bought a new position in Uniqure in the 2nd quarter worth approximately $602,000. Wells Fargo & Company MN boosted its stake in Uniqure by 24.2% in the 3rd quarter. Wells Fargo & Company MN now owns 17,829 shares of the biotechnology company’s stock worth $649,000 after purchasing an additional 3,472 shares during the period. Bank of New York Mellon Corp boosted its stake in Uniqure by 12.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 18,747 shares of the biotechnology company’s stock worth $682,000 after purchasing an additional 2,129 shares during the period. BlackRock Inc. boosted its stake in Uniqure by 3.6% in the 3rd quarter. BlackRock Inc. now owns 481,106 shares of the biotechnology company’s stock worth $17,507,000 after purchasing an additional 16,680 shares during the period. Finally, Credit Suisse AG boosted its position in shares of Uniqure by 20.8% during the 3rd quarter. Credit Suisse AG now owns 28,271 shares of the biotechnology company’s stock valued at $1,028,000 after acquiring an additional 4,859 shares during the last quarter. 61.16% of the stock is owned by institutional investors and hedge funds.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Featured Article: Hedge Funds
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.